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Summary  
OBJECTIVE: Outcomes after changing anti-epileptic drugs (AEDs) have largely been studied in 
single cohort series. We recently reported the first study to examine this question in a controlled 
manner. Here, we expand on these results by using a matched, prospective methodology applied 
to both uncontrolled and well-controlled patients taking any AED. 
METHODS: We reviewed all outpatient notes over a 9-month period and identified patients with 
focal epilepsy on monotherapy. We classified those who switched AED as case patients, with 
those remaining on the same drug serving as controls. We matched cases with controls for 
seizure status (seizure-free in the preceding six months or not), current AED, and number of 
failed AEDs. We subsequently assessed outcome six months later.    
RESULTS: Seizure-free patients who switched drug (n=12) had a 16.7% rate of seizure 
recurrence at six months, compared to 2.8% among controls remaining on the same drug (n=36, 
p=0.11). There was a 37% remission rate among uncontrolled patients who switched drug 
compared to 55.6% among controls (n=27 per group, p=0.18). Uncontrolled patients who had 
previously tried more than one AED were somewhat less likely to enter remission (p=0.057). 
Neither AED mechanism of action nor change in dosage impacted outcome.  
SIGNIFICANCE: Here we provide further estimation of the modest risk (~14%) associated with 
switching AEDs in patients in remission compared to being maintained on the same regimen. 
Uncontrolled patients were no more likely to enter remission after a drug switch than they were 
after remaining on the same drug, suggesting that spontaneous changes in disease state, and not 
drug response, underlie remission in this population. 
 
Keywords: Antiepileptic drugs, Seizure recurrence, Seizure remission 
Key Points: 
- Seizure-free patients who switch drug have approximately a 14% additional risk of seizure 
recurrence compared to remaining on the same drug. 
- Uncontrolled patients who remain on the same drug are just as likely to go into remission as 
those who switch to a different drug.  
  
Introduction 
 With the increasing availability of pharmacologically distinct antiepileptic drugs (AEDs) 
comes an increasing need to understand their efficacy relative to each other. Randomized head-
to-head trials in newly-diagnosed patients, a number of which have been performed in recent 
years1-4 provide crucial data to inform initial treatment decisions, but leave us none the wiser 
about treatment decisions that might be necessary later, if the chosen drug fails or is not 
tolerated. Essentially, the question is not just whether one drug works better than others, but 
whether one drug works in different patients than others. The only way to ascertain this is to 
have the same patient serially treated with several agents to see if there are differences in 
outcome. 
 Such studies have been performed5-8, and have established the rate of seizure control over 
multiple AED trials. But all of these are single cohort studies, without a control group of any 
kind. Furthermore, looking at serial outcome after initial AED failure tells only half the story of 
differences between AEDs. The other half is serial outcome after AED success; this remains 
largely unstudied, as physicians and patients are understandably disinclined to alter therapy when 
seizures are not occurring. Nonetheless, in clinical practice it is frequently necessary to change 
AEDs in seizure-free patients due to side effects, pregnancy planning, or concerns about long-
term consequences9. 
 Our group recently published the first study to provide data regarding these two issues10. 
We found first, that seizure-free patients had a modest but clinically important risk of seizure 
recurrence when switched to a different AED; and second, that patients who were not seizure-
free were as likely to have a remission of seizures if left on the same drug as they were if 
switched to another agent. Yet that study had a number of important limitations. It was 
  
retrospective, and as with any such study, the groups compared had noteworthy differences 
between them in ways that could have changed outcome, such as the number of prior AEDs 
failed. Furthermore, the group who were changing drugs was entirely composed of patients 
taking carbamazepine or phenytoin who were being switched to newer-generation AEDs; thus, 
the generalizability of these data to other types of AED switches remains uncertain. 
 Here we report the outcome of AED switching in both seizure-free and non-seizure-free 
patients in a methodologically improved manner that makes the results more widely applicable to 
the epilepsy population. We looked at patients switching from any AED to any other, rather than 
merely from older to newer drugs; we assessed outcome prospectively rather than 
retrospectively; and we matched the case and control patients by the AED they were taking - to 
eliminate any effects pertaining to specific drugs - and the number of prior AEDs they had failed, 
as this is the most important prognostic factor in treatment). 
 
Methods 
 We reviewed all outpatient encounter notes at the Jefferson Comprehensive Epilepsy 
Center between February and October 2012. Study design is outlined in Figure 1. Inclusion 
criteria were a diagnosis of focal epilepsy and treatment with a single AED; selection of patients 
was done in a retrospective manner. Neither patients nor providers were made aware of inclusion 
in this study. We then classified patients as seizure-free or non-seizure-free as of the index date. 
For case patients, the index date was the date in which the patient switched medications; for 
controls, the appointment date when identified was used. Patients were considered seizure-free if 
they had had no seizures in the six months prior to the index date while taking the single AED 
(generalized tonic-clonic,  focal with impairment of consciousness and focal with observable 
  
manifestations were counted; isolated auras were not); other patients were considered not 
seizure-free. Patients for whom a discernible seizure status on monotherapy at six months could 
not be established were excluded. We recorded patient age, gender, current AED and number of 
AEDs previously failed. The latter were tabulated from chart review. All medications previously 
tried were counted, regardless of the reason of discontinuation. In the case of patients who had 
previously undergone surgical resection for epilepsy, we counted only drugs failed since surgery.  
 Patients were then categorized according to AED management. We classified patients 
who had their AED changed to a different (single) AED during the recruitment period as cases. 
Patients who remained on the same AED during this period were categorized as controls. Cases 
were then matched with controls according to seizure-status as of the index date, with seizure-
free cases matched with seizure-free controls, and non-seizure-free cases with non-seizure-free 
controls (see Figure 1). Seizure-free patients were matched with three controls, while non-
seizure-free patients were each paired with one control. Matching ratios differed because of the 
number of available controls within each group. Cases were matched with controls taking the 
same AED before the index date and who had failed the same number of AEDs. If multiple 
candidates matched a given case in these parameters, a control was chosen chronologically from 
the earliest index date. When no exact match for previous number of AEDs was available, a 
control on the same drug with the closest number of failed AEDs was used; if multiple 
candidates remained at this point, the control with the index date closest to the case’s was used. 
 Finally, patients were prospectively followed for at least six months from the index date 
to assess seizure status. For case patients, the follow-up period was counted from the date in 
which they started monotherapy with the new AED; if no known date was available, we assumed 
a four week period for medication titration. Seizure status was evaluated beginning at six 
  
months, and patients’ outpatient notes were periodically re-evaluated by the authors over the 
following year. Patients were considered seizure-free at six months if they had no seizures 
(excluding auras) during this follow-up period. In order to maximize outcome data and avoid 
bias, patients not seen in clinic for follow-up were telephoned and asked to report on seizure 
recurrence and medication changes. There were six case patients who were rapidly switched off 
of their new AED due to side-effects or cost, and put on another new drug. For these patients, we 
ignored the intervening brief treatment, with the rationale that this would not bias efficacy 
outcome in either direction, and considered them to have switched from their original to the 
latest AED. Patients with no follow-up at six months were removed from the study. Cases who 
did not ultimately switch drugs were also removed. For removed cases, their corresponding 
controls were also excluded. Controls with no follow-up were replaced (preserving the 3:1 and 
1:1 matching ratios for seizure-free and non-seizure-free groups, respectively). New controls 
were selected from the initial pool of controls that remained un-matched, using the same 
matching algorithm described above. For patients who underwent further medication changes, 
had neurosurgical procedures or passed away, outcomes were recorded if a six month seizure 
status on monotherapy could be established. As a secondary outcome measure, we examined 
outcomes one year after index date, but did so only in those for whom monotherapy seizure 
status could be determined for a full year prior to the index to avoid introducing a bias due to 
asymmetry of observation times. 
 A logistic regression model was used to analyze seizure freedom and the effects of other 
variables on seizure freedom. The covariates considered were seizure status before index date 
(seizure-free vs. refractory), cohort type (case vs. control), number of AEDs failed, duration of 
AED trial (log transformed), number of days seizure-free before index date (log transformed, for 
  
seizure-free patients only), and gender. The final parsimonious model, selected in stepwise 
fashion using Akaike Information Criterion, included seizure status before index date, cohort 
type, and number of AEDs failed. There was a significant association between number of AEDs 
failed and seizure status before index date, so an interaction term between these was also 
included. An interaction term between cohort type and seizure status before index date was also 
included because both variables were critical to the study’s design. Analyses of seizure type, 
dose increase, and drug mechanism of action were done using Chi-squared or Fisher’s exact tests 
as appropriate. This study was approved by the Institutional Review Board of Thomas Jefferson 
University. 
 
Results 
Appointment records of 2,734 patient visits were reviewed, with 547 patients meeting 
inclusion criteria. After matching, 102 patients were included in this study. There were 39 case 
patients (those who had their AED changed), of whom 12 were seizure-free at the index date. 
The remaining 63 patients were controls, comprised of 36 seizure-free (matched to the 12 
seizure-free cases) and 27 non-seizure-free patients (matched to the 27 non-seizure-free cases). 
Baseline characteristics for both groups are presented in Table 1. Age and gender were similar 
across the two populations. The groups were also similar for age of onset and duration of 
epilepsy. Among non-seizure-free patients, there was a large difference in seizure frequency 
between cases and controls. However, this effect was due to two cases having upwards of three 
seizures per day during the six month recruitment period. (The next highest frequency, after 
these two, was 32 seizures in six months.) When these two case patients are excluded, seizure 
frequency is comparable between the two groups, as shown in Table 1. Case and controls also 
  
had similar number of previously failed drugs. The most common reason for drug switch was 
seizure, followed by side-effects. Case patients were significantly less likely to be seizure-free at 
the index date (95% CI 0.14-0.76; p=0.011); this is expected, as a change in AED would often be 
prompted by continued seizures.  
Data on drug prevalence is shown in Table 2. The distribution of AEDs before switch 
between cases and controls was largely comparable, with levetiracetam being the most common 
AED in both groups. The disparity in gabapentin prevalence between cases and controls was due 
to the fact that there were no control patients on the drug. A lack of controls for certain case 
patients also accounts for the difference in zonisamide and valproate prevalence. For cases, the 
most common drug to switch to was lamotrigine, followed by levetiracetam.  
Raw data on seizure outcomes at six months are shown in Table 3. Of 12 seizure-free 
case patients, there were 2 (16.7%) who had a recurrent seizure within six months of the drug 
change, compared to 1 of 36 controls who had a spontaneous recurrence within 6 months of the 
index date (2.8%). This difference was not statistically significant, likely due to the small sample 
size, but may be viewed as clinically important, as the incremental risk of seizure recurrence 
with drug switch, compared with remaining on the existing agent, was 13.9%. For non-seizure-
free patients, 10 of 27 (37%) cases became seizure-free at six months, while 15 of 27 controls 
(55.6%) achieved seizure remission. This difference was not significant. 
Odds ratios are shown in Table 4. For seizure-free patients, odds of remaining seizure-
free were not significantly different in cases relative to controls, nor was the number of 
previously failed AEDs a significant predictor of seizure outcome. For non-seizure-free patients, 
the odds of becoming seizure-free at six months were also no different for cases than for 
controls. There was a trend toward non-seizure-free patients having failed 2 or more drugs being 
  
less likely to enter a 6-month remission compared than those who had failed only a single drug 
(OR 0.19, 95% CI: 0.03-1.04, p=0.057). A similar trend was seen for rising number of failed 
drugs being less associated with remission (Chi-square test for trend, p=0.061). We also 
examined whether the number of seizures a patient had had during the 6 months prior to index 
date predicted the likelihood of remission, and found a trend toward patients having three or 
more seizures during this period being less likely to become seizure-free in follow-up compared 
to those having only one or two seizures (OR 0.22, 95% CI 0.05-1.06, p=0.062). Neither age, nor 
gender, nor type of seizure (focal motor, complex partial, generalized tonic-clonic) was found to 
be a significant predictor of outcome in either group. 
We followed patients out to one year when sufficient follow-up data were available. For 
seizure-free patients, we restricted this analysis to those who had been seizure-free for one year 
prior to their index date so that there was no bias created by assessment of longer duration post-
index than pre-index. The 1-year outcomes are shown in Table 5. Overall, the results were fairly 
similar to those seen at six months. Again, there was a trend toward those having failed 2 or 
more AEDs being less likely to enter remission (OR 0.18, 95% CI 0.03-1.09, p=0.065). 
However, number of seizures in the prior 6 months was no longer found to be significant 
predictor (OR 0.39, 95% CI 0.08-1.8, p=0.38).  
Medication titration is a potential reason for seizure recurrence, so we reviewed our 
cohort to determine whether any patients had seizures during their medication titration period; 
we found 4 instances of this. In one case, the patient had a seizure while on low doses of both 
their original and new AEDs (levetiracetam and lamotrigine, respectively) but became seizure-
free for over 6 months once a therapeutic dose of lamotrigine was reached. Three other patients 
  
had seizures during the titration period but continued to have seizures once titration was finished; 
thus, the event occurring during the titration period did not affect their eventual outcome status. 
In the 27 patients who were not seizure-free but remained on the same drug, 11 had a 
dose increase, while 16 remained on the same drug at the same dose. Seven (64%) of the former 
became seizure-free at six months, compared to 8 (50%) of the latter. At one year, remission 
rates were 45% and 38% respectively. There was no clear evidence that dose increase had any 
bearing on likelihood of remission (p>0.5 for 6 month and 1 year comparisons). The difference 
in outcome between patients with symptomatic epilepsy and non-symptomatic was also 
investigated. A similar proportion of symptomatic patients were identified within both case and 
control groups, and seizure recurrence rate at six and twelve months was found to be similar 
between symptomatic and non-symptomatic patients (data not shown).  
To determine if drug mechanism of action played a role, we categorized drugs as being 
sodium channel (phenytoin, carbamazepine, oxcarbazepine, lamotrigine, lacosamide and 
zonisamide) or non-sodium channel agents (all others) and investigated whether those switching 
between categories were more likely to have a change in seizure outcome (seizure-free to non-
seizure-free, or vice versa) than those switching within a drug category. There was a trend 
toward more changes in outcome with switch in drug category (p=0.076), but this borderline 
result was driven overwhelmingly by the tendency of patients on sodium channel drugs to have 
similar outcomes when changed to other sodium channel drugs, and the numbers in individual 
categories are too small to allow for meaningful conclusions. 
 
Discussion 
 The present investigation is the first to utilize a prospective, matched design to study 
  
seizure outcome in patients treated with different AEDs serially in monotherapy. There were two 
major findings. Regarding those who were not seizure-free, we found that the likelihood of 6-
month remission was equally high if the patient were left on the same medication than if 
switched to another. In contrast to our prior study10, all AEDs were included in this investigation, 
and cases and controls were matched for initial AED; thus, this is not a phenomenon related to 
specific drugs. Furthermore, since cases and controls were matched by number of AEDs failed, 
which is the most important prognostic factor in serial treatment outcome8, our result is not an 
artifact of the controls being “easier” patients than the cases. Thus, there was no evidence that 
changes in drug therapy led to improvements in outcome in the non-seizure-free population.  
 Thus, our findings suggest that “successes” in serial AED studies may be spontaneous 
remissions rather than true drug effects. This is line with the results of a recent investigation 
which utilized natural history to simulate drug trials and also found that presumptive treatment 
effects, and placebo effects, are instead likely due to natural fluctuations in the disease11. Some 
serial AED treatment studies involved a more treatment-resistant cohort than ours5,7, but others, 
like us, examined patients throughout the spectrum of treatment resistance8,12. Our non-seizure-
free patients had a high rate of subsequent 6-month remission in comparison to other studies; this 
is likely due to the fact that a considerable fraction of our patients had had only a single seizure 
in the prior 6 months, which may make them more somewhat likely to remit whether there is a 
new drug or not. Nonetheless, the lack of effect of AED switching on outcome appears to hold 
regardless of seizure frequency. 
 The second major result pertains to the seizure-free patients. Our findings suggest about a 
14% risk of seizure recurrence when a patient who has been free of seizures is switched to 
another agent. This is a clinically meaningful difference which likely did not reach statistical 
  
significance due to our sample size; yet validation of this finding comes from our prior 
investigation, which yielded very similar results10. While the previous study included as cases 
only patients taking phenytoin or carbamazepine, the present one includes patients taking any 
AED; this makes the results much more generalizable to the population of adults with focal 
epilepsy. Furthermore, since we matched patients by the specific AED they were taking, and by 
the number of prior AEDs failed, our new data are not biased by variations in AED effects, nor 
by prior difficulty in obtaining seizure control. Thus, in counseling seizure-free patients with 
focal epilepsy, the additional risk of recurrence upon switching to a new agent, based upon two 
separate studies, appears to be approximately 14% over 6 months. Recurrence in a seizure-free 
patient has the potential for a number of negative consequences, including injury, social 
embarrassment, employment difficulty, and loss of driving privileges. This must be weighed 
against the potential benefits of AED switch in certain circumstances, including improved 
quality of life from reduction in side effects13, improved compliance with less frequent dosing 
intervals14, reduced teratogenicity in patients trying to conceive15, and reversal of chronic AED-
related metabolic conditions such as hyperlipidemia or polycystic ovary syndrome9, 16-18. 
Additional studies with larger cohorts will be needed going forward to further validate the results 
our two investigations, and perhaps ascertain whether certain subgroups are at greater or lesser 
risk of seizure recurrence with drug switch. 
 Patients taking sodium-channel-blocking AEDs had a tendency to remain in the same 
outcome class when switched to other sodium channel agents, though these were only statistical 
trends, and the findings may have been limited by the sample sizes of groups taking various 
AEDs. Thus, evaluation of what might be called “rational sequential therapy”, based upon 
mechanism of action, will require larger studies with greater numbers of patients. We found no 
  
evidence that dose increases had impact upon outcome, consistent with findings from prior 
studies that the large majority of patients who become seizure-free do so at modest AED doses19. 
This implies that good outcomes in patients after AED dose increase are also more likely to be 
spontaneous remissions than true drug effects. 
 Our study is limited by the modest sample size of the seizure-free group who switched 
drugs; however, our findings in seizure-free patients are strikingly similar to those obtained in 
our prior, unmatched study10, suggesting that the results are reproducible despite the sample size. 
Our study is also limited by being non-randomized; there are doubtless unmeasured differences 
between those patients who were left on the same drug and those who were switched, as such 
decisions are highly individualized. Such differences might include the presence or absence of 
isolated auras, variability in seizure frequency, and the underlying etiology of epilepsy. 
Performing the ideal study would entail randomizing patients to remain on their current AED or 
switch to another one; such a study would require large numbers, and recruitment would be 
daunting. Thus, despite its limitations, the present type of study may be the only feasible means 
to obtain data regarding serial efficacy of AEDs. 
 We have previously posited two models of relative AED efficacy10. In one model, each 
AED “covers” a somewhat different segment of the epilepsy population, such that efficacy may 
sometimes be dependent upon the individual agent. This is the model implicitly employed by 
many practitioners, including drug trialists, who continue to try one AED after another in 
resistant patients in hopes of finding the “magic bullet” to stop a given patient’s seizures. This 
model is appealing for its refusal to succumb to therapeutic nihilism7, though whether hope 
should supplant data is an ethically fraught issue. In the second model, the various agents are 
almost wholly overlapping in their patient spectra, such that, effectively, “if you’ve failed one, 
  
you’ve failed them all”. This model fits with the practice algorithm of epilepsy surgery 
proponents, who point to data showing the very low remission rate with serial AED trials in 
resistant patients8,12, and whose perspective is bolstered by our data in the non-seizure-free 
population, for whom alterations in therapy had no apparent effect on outcome. 
 There could conceivably be differing segments of the population for which each model is 
accurate. It is also possible that the truth is at neither end of the spectrum, but somewhere in 
between: in other words, with AEDs having moderate, but not large, differences in their 
coverage. Our data suggest that for most patients, most drugs will work, with perhaps one in 
seven having an outcome dependent upon a certain AED. But failure of 2 or more AEDs 
identifies a subset for whom there is no evidence of genuine drug efficacy, even with serial trials, 
consistent with the second model described above. 
 Two further goals, then, present themselves to advance the field of AED clinical 
pharmacology. The first is to determine whether certain drugs are more or less “overlapping” in 
their efficacy spectra than others; this would allow for rational serial AED therapy, as opposed to 
the current practice of choosing based upon physician preference or other clinical factors. The 
second is to address the conundrum that no progress has been made in attacking AED resistance, 
with similar proportions of patients remaining treatment-resistant over time despite the 
development of many new AEDs, some with novel mechanisms6,12. This suggests that many 
patients with epilepsy have a disease whose mechanism is radically different from the ones 
addressed by all currently available AEDs, which appear to largely treat the same group of drug-
amenable patients. 
 In summary, our data suggest that most outcome changes seen in patients with resistant 
epilepsy may be spontaneous rather than due to therapeutic alterations. Changes in therapy may 
  
still sometimes be worthwhile to achieve a palliative goal, such as reduction in generalized tonic-
clonic seizures, or prevention of status epilepticus. Most treatment-amenable patients appear 
likewise to have similar responses to various AEDs -- in this case, positive responses -- but 
perhaps one in seven may depend upon a particular agent or agents for seizure freedom, and the 
risk of seizure recurrence must be balanced against various potential benefits (e.g. mitigation of 
side effects) when there is reason to believe that such benefits may accrue. 
  
  
Tables 
 
Table 1 
Patient demographics  
  Cases Controls p-value 
Number of patients 39 63   
Age (years) 44.8±17.4 47.8±14.4 0.335 
Gender (male) 22 (56.4%) 30 (47.6%) 0.389 
Age of seizure onset (years) 35.6±19.7 34.5±18   
Duration of epilepsy (months) 124.3±130.9 141.55±159.3   
Number seizure-free 12 (30.7%) 36 (58.1%) 0.011 
Monthly seizure-frequency (if non-seizure-free) 
(seizures/month) 7.9±26.3 0.6±1.1 0.023 
After removal of two outlier cases* 0.9±1.2 0.6±1.1 0.055 
Seizure-free period (if seizure-free) (months) 39.8±29 71.4±81.3 0.197 
Number of drugs failed 0.9±1.1 1.16±1.8   
Reason for switch       
Seizures 20 (51.3%)     
Side-effects 14 (35.9%)     
Cost 2 (5.1%)     
Long-term health effects 1 (2.6%)     
Unknown 2 (5.1%)   
 
*See main text 
  
  
Table 2 
Drug usage 
 Before switch After switch 
Drug  Cases (n=39) Controls (n=63) Cases (n=39) 
LEV 15 23 8 
PHT 6 8 0 
CBZ 4 8 2 
ZNS 2 8 8 
LTG 3 3 12 
LAC 1 1 6 
OXC 2 5 1 
GBP 2 0 1 
TPM 2 6 0 
VPA 2 1 0 
PHB 0 0 1 
 
LEV=levetiracetam, PHT=phenytoin, CBZ=carbamazepine, ZNS=zonisamide, 
LTG=lamotrigine, LAC=lacosamide, OXC=oxcarbazepine, GBP=gabapentin, TPM=topiramate, 
VPA=valproate, PHB=phenobarbital  
 
 
 
  
  
Table 3 
 6 months 12 months 
Status at index 
date Group N 
Seizure-
free 
Recurrent 
seizures 
Seizure-
free 
Recurrent 
seizures 
Seizure-free Cases 12 10 (83.3%) 2 (16.7%) 7 (77.8%) 2 (22.2%) 
  Controls 36 35 (97.2%) 1 (2.8%) 27 (96.4%) 1 (3.6%) 
Non-seizure-free Cases 27 10 (37%) 17 (63%) 8 (29.6%) 19 (70.4%) 
  Controls 27 15 (55.6%) 12 (44.4%) 11 (44%) 14 (56%) 
Outcomes at six and twelve months  
 
 
 
 
 
 
 
 
 
 
 
  
  
Table 4 
Six month outcome analysis  
Status at index date Comparison Odds ratio 95% CI p-value 
Seizure-free Cases versus controls 0.13 (0.01, 1.53) p = 0.11 
  Previous failed AED * * p = 0.579 
Non-seizure-free Cases versus controls  0.47 (0.15, 1.38) p = 0.18 
  Previous failed AED, ≥2 0.19 (0.03, 1.04) p = 0.057 
 Number of seizures†, ≥2  0.22 (0.05, 1.06) p = 0.062 
 
*Calculated using Fisher’s Exact test; odds ratio not determinable. †In six months prior to index 
date. 
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